RAPT Therapeutics Announces Board of Directors Appointment

RAPT Therapeutics announced Mary Ann Gray, Ph.D., President of Gray Strategic Advisors, has joined its Board of Directors.

"We are pleased to welcome Mary Ann to our Board, as she brings a wealth of scientific and financial expertise from her time investing in and covering biotech companies, as well as broad leadership experience guiding companies as they develop key therapeutics with a wide range of pharmacological applications," said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics. "We believe Mary Ann will offer both scientific and business insights as we continue to grow the company and advance FLX475 for the treatment of multiple cancers and RPT193 for the treatment of allergic inflammatory diseases."

Dr. Gray is President of Gray Strategic Advisors, a biotechnology strategic planning and advisory firm. Previously, she served as Senior Analyst and Portfolio Manager of Federated Kaufmann Fund where she was responsible for over $1 billion in healthcare investments including biotechnology, specialty pharmaceutical, pharmaceutical and healthcare services companies. Prior to Federated, she served as a biotechnology equity research analyst at multiple firms. Earlier in her career, she worked as a senior scientist both at Schering Plough Research and NeoRx Corporation. She currently serves on the boards of Seneca Biopharma Inc. and Sarepta Therapeutics, Inc. and previously served on the board of many public and private biotech companies. Dr. Gray holds a Bachelor of Science degree from the University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine.

"RAPT Therapeutics, with its integrated platform for drug discovery, has the potential to truly disrupt the treatment paradigm for multiple disease areas – from cancer to inflammation," said Dr. Gray. "I look forward to working with the executive team and Board at this pivotal time for the Company, with exciting data readouts from both lead programs expected by mid-2020."

Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.